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from a prognostic point of view but also appear to be able to
identify those patients likely to beneﬁt from therapeutic inter-
vention [9,10]. The prognostic utility of the presence of SIRS cri-
teria has previously been described in ALD patients with ACLF [7].
This may in part explain the prognostic accuracy of the GAHS as
white cell count is a principle component of both SIRS and GAHS.
In conclusion, it is unrealistic to suggest that biopsy is essen-
tial for the diagnosis and prognosis of patients with alcoholic
hepatitis. Whilst biopsy may be necessary in cases of diagnostic
uncertainty and for the characterisation of patients for research
purposes, clinical criteria for diagnosis and identiﬁcation of
patients for treatment are readily available for the majority of
patients with alcoholic hepatitis. The aim should be to assess
such patients promptly on presentation rather than to rely upon
strategies based upon histology which may delay assessment or
be difﬁcult to obtain outside specialist centres.
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Reply to: ‘‘Is a liver biopsy necessary in alcoholic hepatitis?’’
To the Editor:
We thank Drs. Forrest and Gleeson for their interest in our paper
[1]. Their letter makes two points; one clinical and the other
logistical, which will be addressed in turn.
Clinical
Our study describes the value of early liver biopsy (between
days 1 and 7 from admission) in patients presenting with acute
decompensation of cirrhosis. As correctly identiﬁed by Forrest
and Gleeson, only biopsies taken early in the admission are valu-
able in interpreting the cause of decompensation. However, we
beg to differ with them on the relative importance placed on
hyperbilirubinaemia as a key feature of ASH versus other causes
of decompensated alcoholic liver disease. Indeed, in the paper
they cite by Katoonizadeh et al. [2], patients with acute-on-
chronic liver failure (ACLF) presenting with hyperbilirubinaemia
had most commonly sepsis with high SIRS, conﬁrmed by ductu-
lar bilirubinostasis, which was also an independent prognostic
factor. In our series, mean bilirubin values of 227 lmol/L in
heavy drinkers with onset of jaundice less than 1 month from
the acute admission ﬁts with other studies addressing diagnos-
tic criteria in ASH [3,4]. However, 50% of patients with high SIRS
had no signiﬁcant histological features of ASH using the grading
system we describe and yet sepsis related mortality was higher
in these patients with their biopsies showing signiﬁcant
cholestasis. Thus, high bilirubin cannot distinguish infection
from the hepatic inﬂammation of ASH in decompensated
cirrhosis and their respective management is completely
different.
Louvet et al. show that in patients failing corticosteroid treat-
ment of ASH, mortality from infection is high, suggesting that cor-
ticosteroidsmay promote increased infection in these patients and
precipitate poor outcome [5]. It follows that the practice of clinical
grading of AH in a decompensated alcoholic cirrhotic is likely to
signiﬁcantlyunderestimate infection, adversely impact on survival
and inappropriately target anti-inﬂammatory therapies fromthose
patients inmost need, i.e. thosewith severe histological ASH. Thus,
whilst desirable to make a rapid diagnosis of ASH to institute
appropriate therapy, to commence therapy on clinical grounds
may be more hazardous to the patient than availing objective
biopsy conﬁrmation. Additionally,mostof the largeFrenchcortico-
steroid trials includedpatients after a liver biopsy to diagnoseASH.
Therefore, to suggest use of corticosteroids without liver biopsy
conﬁrmation is not based on evidence.
In relation to use of widely published scoring systems such as
modiﬁed DF, MELD and more recently GAHS [6,7], we agree that
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they have utility in highlighting patients most at risk of having
severe ASH. However, as acknowledged by Forrest and Gleeson
for DF, all these scores draw upon criteria such as clotting time
which are prone to signiﬁcant variations between labs, whilst
MELD and GAHS also employ measures of renal function, which
in the context of advanced liver disease, are unreliable and
change with clinical status (e.g. urea with ﬂuid status, feeding
and GI bleeding). The GAHS score perhaps has advantage over
others by including white cell count thereby reﬂecting compo-
nent of SIRS but as stated above, caution should be exercised
when interpreting SIRS in a decompensated alcoholic, as this
encompasses all patients with alcoholic liver disease and ACLF
(including sepsis) and not just ASH, requiring quite different
management. Furthermore, our data shows that not only is the
area under receiver operator curves higher for the ASH
histological score compared to DF or MELD, its speciﬁcity is
markedly higher with predictive utility for deﬁning 28-day
mortality.
Logistical
population at risk of ASH in the UK, we believe our data clearly
afﬁrms the importance of liver biopsy to make a diagnosis of ASH
and thus facilitate appropriate triage to therapy. The value added
of liver biopsy in this setting is that it will also allowmore reliable
interpretation of data from clinical trials of new interventions by
accurately deﬁning the ‘at risk’ severe ASH population with the
most to gain from intervention, whilst also clearly identifying
patients who have other causes of liver disease.
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JOURNAL OF HEPATOLOGYForrest and Gleeson correctly highlight the signiﬁcant burden of
alcoholic liver disease admissions in the UK. However, the num-
ber of purported alcoholic hepatitis cases is a small fraction of the
admissions with alcoholic cirrhosis and indeed those with high
SIRS scores [2]. Our own data over 3 years demonstrates that
patients with a clinical presentation suggestive of ASH have a fre-
quency of about two cases per month in a tertiary unit with spe-
cialist interest in this disease. The important point here is how to
correctly identify ‘true’ severe alcoholic steatohepatitis (ASH)
from those with advanced decompensated cirrhosis, as their early
mortality remains signiﬁcantly high (25–40%) despite optimal
supportive management [8,9]. Appropriate identiﬁcation and
intervention in severe ASH will undoubtedly reduce mortality
and warrants the necessary resource allocation as seen with con-
ditions such as acute myocardial infarction and stroke, which are
managed in non-tertiary centres, all of whom have access to
interventional radiology and histopathology. The key question
which our paper addresses, therefore, is how to most accurately
identify ASH in the at-risk population and not to consider biopsy
in most patients with alcoholic liver disease for which we
agree with Forrest and Gleeson is not a useful application of
resources.
In conclusion, whilst acknowledging the need for greater
resource allocation to diagnose and expediently treat the growingJournal of Hepatology 2012 vol. 56 j 1420–1429 1429
